Market Overview

Galena Biopharma Reports Data Demonstrate Role of NeuVax in Preventing Breast Cancer Recurrence


Galena Biopharma (NASDAQ: GALE) presented data from the Phase 1/2 clinical trial of NeuVax™ (nelipepimut-S or E75) at the 27th Annual Meeting of the Society for Immunotherapy of Cancer. The event is being held October 26-28, 2012 at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, Maryland.

The poster presentation entitled: "Trends in Circulating Tumor Cells (CTCs) in Multiple Adjuvant Trials of HER2-Directed Peptide Vaccines (PVs)" measured CTCs from blood samples from NeuVax (nelipepimut-S or E75) patients using the CellSearch® system (Veridex). CTCs are cells that have detached from the primary breast tumor and circulate in the bloodstream, and may then cause the growth of additional tumors (metastases) in different tissues. These recurrences may occur soon after the original cancer or many years after the initial treatment. Increased presence of CTCs predicts the likelihood of a recurrence of the cancer resulting in poor disease-free survival (DFS) and overall survival (OS), suggesting a dormancy of isolated micrometastases.

These results showed a total of 26 patients receiving NeuVax had at least two CTC

See full press release

Posted-In: News Guidance Management Global


Related Articles (GALE)

View Comments and Join the Discussion!